AMRX Q3 2025 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q3 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$785M+11.7% YoY

Gross Profit

$274M34.9% margin

Operating Income

-$117,000-0.0% margin

Net Income

$2M0.3% margin

EPS (Diluted)

$0.01

QoQ Revenue Growth

+8.3%

Cash Flow

Operating Cash Flow

$118M

Free Cash Flow

$103M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$3.6B

Total Liabilities

$3.7B

Stockholders' Equity

-$109M

Cash & Equivalents

$201M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$785M	$702M	+11.7%
Gross Profit	$274M	$270M	+1.6%
Operating Income	-$117,000	$89M	-100.1%
Net Income	$2M	-$156,000	+1618.6%

Revenue Segments

Amneal Specialty Pharma Segment

$125M100%

Geographic Segments

Specialty Segment

$125M100%